Company intelligence / Profile preview
Liperate Therapeutics
Gwynedd Valley, Pennsylvania, United Statesliperate.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Liperate Therapeutics is a pre-clinical stage biotechnology company focused on developing novel small molecule therapies for inflammatory and fibrotic diseases. The company's lead program targets GPR84, a G protein-coupled receptor that plays a significant role in modulating immune cell activation and inflammatory responses. By inhibiting GPR84, Liperate aims to provide effective treatments for conditions such as ulcerative colitis and nonalcoholic steatohepatitis (NASH). The company is led by experienced industry veterans and is advancing its pipeline toward IND-enabling studies.
- Therapeutic areas
- GastroenterologyPulmonology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Liperate Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liperate Therapeutics.